2023
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol
Kitay B, Murphy E, Macaluso M, Corlett P, Hershenberg R, Joormann J, Martinez-Kaigi V, Nikayin S, Rhee T, Sanacora G, Shelton R, Thase M, Wilkinson S. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol. Psychiatry Research 2023, 330: 115585. PMID: 37935086, DOI: 10.1016/j.psychres.2023.115585.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyMajor depressionSuicidal ideationRelapse preventionBehavioral therapyStudy protocolHigh riskClinical trial study protocolLong-term treatment approachKey secondary outcomesTrial study protocolHigh relapse rateHigh-risk populationSignificant suicidal ideationHospital dischargeSecondary outcomesPrimary outcomeRelapse rateFeasibility trialEsketamineTreatment approachesPatientsSuicide attemptsTherapySupplemental indications
2018
Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression
Wilkinson ST, Holtzheimer PE, Gao S, Kirwin DS, Price RB. Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression. Biological Psychiatry 2018, 85: 454-465. PMID: 30528745, PMCID: PMC6380941, DOI: 10.1016/j.biopsych.2018.09.004.Peer-Reviewed Original ResearchConceptsClinical outcomesN-methyl-D-aspartate receptor modulatorsLong-term clinical outcomesLong-term treatment outcomesBehavioral interventionsImpairment of neuroplasticityUnderstanding of pathophysiologyStand-alone treatmentTranscranial brain stimulationNeuroplasticity deficitsSymptom burdenElectroconvulsive therapyReceptor modulatorsTreatment outcomesEnhanced neuroplasticityMood disordersDepressive symptomsBrain stimulationTreatment approachesSymptom reductionNeuroplasticityNeuropsychiatric disordersBehavioral therapyDisease statesTherapeutic development
2017
Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression
Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, Sanacora G. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. Psychotherapy And Psychosomatics 2017, 86: 162-167. PMID: 28490030, PMCID: PMC5516265, DOI: 10.1159/000457960.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAdultAntidepressive AgentsCognitionCognitive Behavioral TherapyCombined Modality TherapyDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantFemaleHumansKaplan-Meier EstimateKetamineMaleMiddle AgedPsychiatric Status Rating ScalesRecurrenceRemission InductionTreatment OutcomeYoung AdultConceptsTreatment-resistant depressionCognitive behavioral therapyAntidepressant effectsKetamine's antidepressant effectsKetamine exposureIntravenous ketamineKetamine infusion therapyWeeks of protocolOpen-label trialLong-term treatmentStandardized clinical protocolCognitive behavior therapyKetamine nonrespondersKetamine respondersRelapse rateMedian timeInfusion therapyClinical protocolsKetamineNeurobiological changesRemissionBehavioral therapyTherapyWeeksBehavior therapy